While the FDA appears to be taking a more active role in leveraging its position to influence drug prices, the majority of efforts to bring down pharmaceutical costs are taking place at the state level.
The year began with President Trump’s accusations that pharmaceutical developers were “getting away with murder,” expectations that an executive order on drug pricing was imminent, and calls from stakeholder groups for the government to use such legislation as the Bayh-Dole Act to force drug makers to bring down high prescription drug costs. However, efforts to reduce drug prices appear to have stalled at the federal level as the major focus of congressional activity turned toward healthcare reform.
While the FDA appears to be taking a more active role in leveraging its position to influence drug prices, the majority of remaining efforts to bring down pharmaceutical costs are taking place at the state level. These state legislative efforts, as BioPharma Dive points out, tend to be aimed at narrow goals—including restricting the tactics of pharmacy benefit mangers (PBMs), tracking increased drug prices, and empowering states to impose penalties on entities that flout regulation—rather than seeking comprehensive reform.
The National Academy for State Health Policy (NASHP), a non-profit, non-partisan academy of state health policymakers, reports the following successful 2017 drug pricing initiatives:
A number of other states have bills currently in committee. Those pending efforts include a California bill that would allow for greater regulation of PBMs, an Illinois bill that would require drug makers to notify purchasers of increases in drug prices 60 days prior to the increase, a New Jersey bill that would authorize the state’s attorney general to negotiate discounts for opioid antidotes on behalf of public entities, and Pennsylvania’s effort to establish a Pharmaceutical Transparency Commission to investigate the reasonability of retail drug prices.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.